Antidote: Sleeping aids

Share this article:
Marc Siegel, MD
Marc Siegel, MD

Americans don't sleep enough. Studies show that when we sleep less than six hours on a regular basis we risk diabetes, heart problems, anxiety, depression, and problems thinking clearly.

When it comes to helping a patient learn to get more sleep, I don't turn to prescribed remedies right away. I start by encouraging patients to sleep in a dark room, to knock off the iPhones and Blackberries before bed, to not drink caffeine or alcohol in the evening, and to teach themselves a ritual to slow their minds down.

Ambien, Lunesta, and Sonota are sedative-hypnotics, which increase a neurochemical, GABA, that slows the brain down. They are generally effective, though studies show they may not prolong sleep more than 30 to 60 minutes on average, and it may take you as long to get to sleep whether you take them or not.

The media has hyped such dramatic sides effects as a person unknowingly driving a car. Most recently, Tom Brokaw publicly said that Ambien made him feel groggy. On the whole, however, Ambien and the other medicines in its group are well tolerated and help many people.

But 60 million prescriptions are written for sleeping pills every year. Not all are necessary, especially when a physician just renews a prescription over and over.

Once again the media bluntly attacks a subtle issue—sleeping pills like Ambien or Lunesta, though frequently overprescribed, are helpful sleeping aids when used appropriately. The fact that they are not always used appropriately is more the fault of physicians and patients rather than the drugmaker.

Marc Siegel, MD, is an internist and professor of medicine at New York University and the author of False Alarm: The Truth About the Epidemic of Fear.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?